Optiscan Imaging (OIL) H1 2026 earnings summary

Executive summary

• $17.75m capital raised to fund clinical studies, regulatory submissions, and R&D initiatives.

• Significant progress in clinical studies for FDA submissions, including first in-human head and neck cancer imaging study.

• Strategic partnerships formed, notably with Australian Clinical Labs for digital pathology.

• Three new clinical devices (InVue®, InForm®, InSpecta®) unveiled and advanced toward commercialisation.

• Enhanced quality management system achieving FDA-ready status across six jurisdictions.

Financial highlights

• Revenue for H1FY26 was $339,227, down 43% year-over-year due to lower Viewn Vivo® sales amid restricted research funding in the US and China.

• Other income was $1,380,209, with R&D incentive income at $1,155,310, lower than the prior period due to a one-off adjustment last year.

• Net loss after tax was $3,395,877, compared to $2,374,663 in the prior year.

• Net assets increased to $22,024,231 from $7,712,014 at June 2025, primarily due to the capital raise.

• Net cash used in operating activities was $4,131,669, with a net increase in cash and equivalents of $13,163,026 for the half-year.

Outlook and guidance

• Focus on progressing clinical studies and regulatory submissions for US FDA approval in 2026.

• Commercial launch of InSpecta® for the veterinary market planned for H2 2026.

• Continued investment in R&D and expansion of product pipeline across medical, pathology, and veterinary applications.